type public traded as nasdaq amgn nasdaq 100 component s & p 500 component sehk 4332 industry biotechnology founded 1980 headquarters thousand oaks california u.s. key people robert a. bradway chairman president and ceo products epogen aranesp kineret enbrel neulasta neupogen nplate vectibix prolia xgeva and sensipar mimpara . revenue us 20.063 billion 2014 1 operating income us 6.191 billion 2014 1 net income us 5.158 billion 2014 1 total assets us 69.009 billion 2014 1 total equity us 25.778 billion 2014 1 number of employees 17 900 december 2014 1 website www.amgen.com amgen formerly applied molecular genetics inc. 2 3 is an american multinational biopharmaceutical company headquartered in thousand oaks california . located in the conejo valley amgen is the world s largest independent biotechnology firm . in 2013 the company s largest selling product lines were neulasta neupogen two closely related drugs used to prevent infections in patients undergoing cancer chemotherapy ; and enbrel a tumor necrosis factor blocker used in the treatment of rheumatoid arthritis and other autoimmune diseases . other products include epogen aranesp sensipar mimpara nplate vectibix prolia and xgeva . contents 1 history 2 timeline 3 acquisition timeline 3.1 acquisition history 4 products 4.1 products developed and then sold off 5 pipeline & clinical trials 6 see also 7 references 8 external links history edit amgen corporate logo 1983 amgen s corporate gulfstream v departs fox field lancaster california the word amgen is a portmanteau of the company s original name applied molecular genetics which became the official name of the company in 1983 three years after incorporation and coincident with its initial public offering . the company s first chief executive officer from 1980 was co founder george b. rathmann followed by gordon m. binder in 1988 4 followed by kevin w. sharer in 2000 . 5 robert a. bradway became amgen s president and chief executive officer in may 2012 following sharer s retirement . 6 the company has made at least five major corporate acquisitions . timeline edit 1980 . william bowes from cetus corporation recruits william salser from ucla to start amgen with a scientific advisory board consisting of normam davidson leroy hood arnold berk john carbon robert schimke arno motulsky marvin h. caruthers and dave gibson . 7 1989 . amgen received approval for the first recombinant human erythropoetin product epogen for the treatment of anemia associated with chronic kidney failure . epogen also marketed by johnson and johnson under the tradename procrit would later be approved for anemia due to cancer chemotherapy anemia due to treatment with certain hiv drugs and for the reduction of the need for transfusions associated with surgery . 8 1991 . in february 1991 amgen received fda approval for neupogen for the prevention of infections in patients whose immune systems are suppressed due to cancer chemotherapy . 9 a 2002 meta analysis found that neupogen treatment reduced the risk of febrile neutropenia by 38 % reduced the risk of documented infection by 49 % and reduced the risk of infection related mortality by 40 % . 10 1998 . in november 1998 immunex a future acquisition of amgen received approval for enbrel etanercept the first rheumatoid arthritis drug targeting tumor necrosis factor alpha tnf alpha . 8 a 2006 assessment by the national institute of clinical excellence of the united kingdom concluded that etanercept and related rheumatoid arthritis drugs later introduced by competitors are effective treatments compared with placebo for ra patients who are not well controlled by conventional dmards improving control of symptoms improving physical function and slowing radiographic changes in joints . 11 a more recent study demonstrated that compared to traditional disease modifying anti rheumatic drugs treatment with etanercept improved survival reduced cardiovascular events and reduced the incidence of hematological cancers . 12 2010 . on june 6 2010 amgen received fda approval for prolia a protein drug for the treatment of post menopausal osteoporosis . 13 in clinical trials prolia reduced the rate of vertebral fractures by 61 % and the risk of hip fractures by 40 % . 14 2010 in november 2010 the fda approved xgeva for the prevention of complications of bone metastases in patients with solid tumors . 15 the clinical trials primarily enrolled patients with breast or prostate cancer . 2012 . illegal marketing practices . the los angeles times reported on december 18 2012 that amgen pleaded guilty and agreed to pay 150 million in criminal penalty and 612 million to resolve 11 related whistleblower complaints . federal prosecutors accused the company of pursuing profits while putting patients at risk . 16 larry husten a contributor at forbes.com elaborates on amgen s illegal marketing practices in this case namely that the government accused amgen of marketing aranesp for indications not approved by the fda and other illegal marketing practices . 17 one of the drugs mentioned in the lawsuit had sales of 492 million in the third quarter of 2012 down 17 % from the same quarter the previous year due to reimbursement problems and label changes . 18 2012 . amgen paid 762 million after pleading guilty to criminal charges of improper promotion and sale of misbranded drugs . 19 2013 . lawmakers inserted text into the fiscal cliff bill that will allow the drugmaker to sell a class of drugs that includes sensipar without government controls for an additional two years . the new york times estimated that the paragraph in the fiscal cliff bill will cost taxpayers an estimated 500 million 20 but other assessments concluded that the change would protect seniors in rural areas and reduce overall medicare spending . 21 22 2015 . in september the company announced it would acquire dezima pharma for more than 1.55 billion . 23 the same day the company announced a collabaration with xencor on 6 early stage immuno oncology and inflammation programmes . as part of the deal amgen will pay 45 million upfront with the deal being worth up to another 1.7 billion . 24 25 2016 . in september the company announced it would purchase the rights to boehringer ingelheims phase i bispecific t cell engager compound bi 836909 now amg 420 for use in the treatment of multiple myeloma . 26 acquisition timeline edit 1994 synergen inc. 27 2000 kinetix pharmaceuticals inc. 28 2002 immunex corporation 29 30 2004 tularik inc. 31 2006 abgenix inc. 32 33 34 2006 avidia inc. 35 2007 alantos pharmaceuticals 36 2007 ilypsa inc. 37 2007 alantos pharmaceuticals holdings inc. 37 2011 biovex group inc. 38 2011 laborat rio qu mico farmac utico bergamo ltda . 39 2012 micromet inc. 40 2012 mustafa nevzat i la 41 42 2012 kai pharmaceuticals 43 2012 decode genetics 2013 onyx pharmaceuticals inc. 44 2015 dezima pharma 23 2015 catherex 45 acquisition history edit the following is an illustration of the company s mergers acquisitions spin offs and historical predecessors amgen amgen founded 1983 as applied molecular genetics synergen inc acq 1994 kinetix pharmaceuticals inc acq 2000 immunex corporation acq 2002 tularik inc acq 2004 abgenix inc acq 2006 avidia inc acq 2006 alantos pharmaceuticals acq 2007 ilypsa inc acq 2007 alantos pharmaceuticals holdings inc acq 2007 biovex group inc acq 2011 laborat rio qu mico farmac utico bergamo ltda acq 2011 micromet inc acq 2012 mustafa nevzat i la acq 2012 kai pharmaceuticals acq 2012 decode genetics acq 2012 onyx pharmaceuticals acq 2013 nextcode genetics spun off 2013 dezima pharma acq 2015 products edit as of december 2013 amgen had twelve approved drugs or therapeutic biologicals for seventeen conditions conditions lists are highly generalized ; see each article for more detail aranesp darbepoetin alfa for anemia blincyto blinatumomab for the treatment of acute lymphoblastic leukemia . 46 enbrel etanercept for various forms of arthritis epogen epoetin also known as procrit ; for anemia neulasta peg granulocyte colony stimulating factor or pegfilgrastim for neutropenia neupogen granulocyte colony stimulating factor for neutropenia nplate romiplostim for chronic immune thrombocytopenic purpura prolia denosumab for postmenopausal osteoporosis sensipar mimpara cinacalcet for primary & secondary hyperparathyroidism a mineral metabolism complication common in patients with kidney failure vectibix panitumumab for colon cancer xgeva denosumab for the prevention of skeletal related events sres pathological fracture radiation to bone spinal cord compression or surgery to bone in adults with bone metastases from solid tumors products developed and then sold off edit kepivance palifermin for oral mucositis sold to biovitrium now swedish orphan biovitrum in december 2008 47 stemgen ancestim for use in combination with filgrastim for mobilizing peripheral hematopoietic stem cells 48 sold to biovitrium now swedish orphan biovitrum in december 2008 47 kineret anakinra for rheumatoid arthritis exclusively licensed to biovitrium now swedish orphan biovitrum in december 2008 47 pipeline & clinical trials edit as of december 2013 amgen had 11 drugs in phase iii clinical trials . 49 in november 2014 the company announced it was halting all trials of rilotumumab in advanced gastric cancer patients after one of the trials found more deaths in those who took the compound with chemotherapy than those without . 50 later in the same week the company in conjunction with astrazeneca reported positive results for brodalumab in a phase iii trial comparing the compound with ustekinumab and a placebo in treating psoriasis . 51 in march 2015 the company announced it would license its phase ii candidate drug amg 714 to developer celimmune who plan to develop the anti il 15 monoclonal antibody for treatment against diet nonresponsive celiac disease and refractory celiac disease . 52 in june 2015 amgen presented phase 2 clinical trial data for their anti cgrp antibody amg 334 for migraine . 53 see also edit california portal companies portal kirin amgen v hoechst marion roussel a uk patent case decided by the house of lords references edit a b c d e f amgen inc. form 10 k annual report for the fiscal year ended december 31 2014 filing date feb 19 2015 . securities and exchange commission . retrieved 2015 03 27 . amgen history official site page accessed january 2 2016 ronald vogel . pharmaceutical economics and public policy . crc press 2007 . isbn 9781439801345 . p. 208 amgen form 10 k annual report filing date mar 24 1998 . secdatabase.com . retrieved jan 8 2013 . amgen form 10 k405 filing date mar 7 2000 . secdatabase.com . retrieved jan 8 2013 . amgen form 8 k current report filing date may 24 2012 . secdatabase.com . retrieved jan 8 2013 . amgen a biotechnology success story from drug development to the mass market . a b drugs fda fda approved drug products . drugs fda fda approved drug products . lyman gh kuderer nm djulbegovic b april 2002 . prophylactic granulocyte colony stimulating factor in patients receiving dose intensive cancer chemotherapy a meta analysis . am . j. med . 112 5 406 11 . doi 10.1016 s0002 9343 02 01036 7 . pmid 11904116 . chen yf jobanputra p barton p et al. november 2006 . a systematic review of the effectiveness of adalimumab etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost effectiveness . health technol assess . 10 42 iii iv xi xiii 1 229 . pmid 17049139 . morgan cl emery p porter d et al. january 2014 . treatment of rheumatoid arthritis with etanercept with reference to disease modifying anti rheumatic drugs long term safety and survival using prospective observational data . rheumatology oxford . 53 1 186 94 . doi 10.1093 rheumatology ket333 . pmid 24140761 . drugs fda fda approved drug products . www.accessdata.fda.gov pdf . fda approves xgeva to help prevent cancer related bone injury . terhune chad 18 december 2012 . amgen pleads guilty to improper marketing of anemia drug aranesp . los angeles times . retrieved 2 february 2013 . husten larry . amgen pleads guilty to misbranding anemia drug aranesp . forbes . retrieved 2 february